Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms
Abstract Parkinson’s disease (PD) is a neurodegenerative disorder with motor deficits due to nigrostriatal dopamine depletion and with the non-motor/premotor symptoms (NMS) such as anxiety, cognitive dysfunction, depression, hyposmia, and sleep disorders. NMS is presented in at least one-fifth of th...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Chinese Neurosurgical Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41016-023-00338-z |
| _version_ | 1797578097486200832 |
|---|---|
| author | Jinmei Sun Wei Zhang Zheng Zachory Wei Xiaopeng Song Liu Jian Feng Jiang Shuanglin Wang Haibo Li Yongbo Zhang Houzhen Tuo The CtrLyin Group |
| author_facet | Jinmei Sun Wei Zhang Zheng Zachory Wei Xiaopeng Song Liu Jian Feng Jiang Shuanglin Wang Haibo Li Yongbo Zhang Houzhen Tuo The CtrLyin Group |
| author_sort | Jinmei Sun |
| collection | DOAJ |
| description | Abstract Parkinson’s disease (PD) is a neurodegenerative disorder with motor deficits due to nigrostriatal dopamine depletion and with the non-motor/premotor symptoms (NMS) such as anxiety, cognitive dysfunction, depression, hyposmia, and sleep disorders. NMS is presented in at least one-fifth of the patients with PD. With the histological information being investigated, stem cells are shown to provide neurotrophic supports and cellular replacement in the damaging brain areas under PD conditions. Pathological change of progressive PD includes degeneration and loss of dopaminergic neurons in the substantia nigra of the midbrain. The current stem cell beneficial effect addresses dopamine boost for the striatal neurons and gliovascular mechanisms as competing for validated PD drug targets. In addition, there are clinical interventions for improving the patient’s NMS and targeting their autonomic dysfunction, dementia, mood disorders, or sleep problems. In our and many others’ research using brain injury models, multipotent mesenchymal stromal cells demonstrate an additional and unique ability to alleviate depressive-like behaviors, independent of an accelerated motor recovery. Intranasal delivery of the stem cells is discussed for it is extensively tested in rodent animal models of neurological and psychiatric disorders. In this review, we attempt to discuss the repairing potentials of transplanted cells into parkinsonism pathological regions of motor deficits and focus on preventive and treatment effects. From new approaches in the PD biological therapy, it is believed that it can as well benefit patients against PD-NMS. |
| first_indexed | 2024-03-10T22:17:38Z |
| format | Article |
| id | doaj.art-62c6145fbd5140a09449eb1e339b0a38 |
| institution | Directory Open Access Journal |
| issn | 2057-4967 |
| language | English |
| last_indexed | 2024-03-10T22:17:38Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Chinese Neurosurgical Journal |
| spelling | doaj.art-62c6145fbd5140a09449eb1e339b0a382023-11-19T12:23:59ZengBMCChinese Neurosurgical Journal2057-49672023-10-019111510.1186/s41016-023-00338-zMesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptomsJinmei Sun0Wei Zhang1Zheng Zachory Wei2Xiaopeng Song3Liu Jian4Feng Jiang5Shuanglin Wang6Haibo Li7Yongbo Zhang8Houzhen Tuo9The CtrLyin GroupClinical Diagnosis and Treatment Center for Parkinson’s Disease, Beijing Friendship HospitalLaboratories of Biological Therapeutic Medical Technology, Department of Neurology, Beijing Friendship Hospital Center for Neurological Disorders, Capital Medical UniversityClinical Diagnosis and Treatment Center for Parkinson’s Disease, Beijing Friendship HospitalMcLean Imaging Center, McLean Hospital, Harvard Medical SchoolLaboratories of Biological Therapeutic Medical Technology, Department of Neurology, Beijing Friendship Hospital Center for Neurological Disorders, Capital Medical UniversityNeuroscience Research Institute, Peking UniversityDepartment of Critical Care Medicine, Airport Hospital of Tianjin Medical University General HospitalDepartment of Critical Care Medicine, Airport Hospital of Tianjin Medical University General HospitalLaboratories of Biological Therapeutic Medical Technology, Department of Neurology, Beijing Friendship Hospital Center for Neurological Disorders, Capital Medical UniversityClinical Diagnosis and Treatment Center for Parkinson’s Disease, Beijing Friendship HospitalAbstract Parkinson’s disease (PD) is a neurodegenerative disorder with motor deficits due to nigrostriatal dopamine depletion and with the non-motor/premotor symptoms (NMS) such as anxiety, cognitive dysfunction, depression, hyposmia, and sleep disorders. NMS is presented in at least one-fifth of the patients with PD. With the histological information being investigated, stem cells are shown to provide neurotrophic supports and cellular replacement in the damaging brain areas under PD conditions. Pathological change of progressive PD includes degeneration and loss of dopaminergic neurons in the substantia nigra of the midbrain. The current stem cell beneficial effect addresses dopamine boost for the striatal neurons and gliovascular mechanisms as competing for validated PD drug targets. In addition, there are clinical interventions for improving the patient’s NMS and targeting their autonomic dysfunction, dementia, mood disorders, or sleep problems. In our and many others’ research using brain injury models, multipotent mesenchymal stromal cells demonstrate an additional and unique ability to alleviate depressive-like behaviors, independent of an accelerated motor recovery. Intranasal delivery of the stem cells is discussed for it is extensively tested in rodent animal models of neurological and psychiatric disorders. In this review, we attempt to discuss the repairing potentials of transplanted cells into parkinsonism pathological regions of motor deficits and focus on preventive and treatment effects. From new approaches in the PD biological therapy, it is believed that it can as well benefit patients against PD-NMS.https://doi.org/10.1186/s41016-023-00338-zCell therapyCognitive impairmentDepressionNeuronal survival and differentiationParkinson’ s disease |
| spellingShingle | Jinmei Sun Wei Zhang Zheng Zachory Wei Xiaopeng Song Liu Jian Feng Jiang Shuanglin Wang Haibo Li Yongbo Zhang Houzhen Tuo The CtrLyin Group Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms Chinese Neurosurgical Journal Cell therapy Cognitive impairment Depression Neuronal survival and differentiation Parkinson’ s disease |
| title | Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms |
| title_full | Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms |
| title_fullStr | Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms |
| title_full_unstemmed | Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms |
| title_short | Mesenchymal stromal cell biotherapy for Parkinson’s disease premotor symptoms |
| title_sort | mesenchymal stromal cell biotherapy for parkinson s disease premotor symptoms |
| topic | Cell therapy Cognitive impairment Depression Neuronal survival and differentiation Parkinson’ s disease |
| url | https://doi.org/10.1186/s41016-023-00338-z |
| work_keys_str_mv | AT jinmeisun mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT weizhang mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT zhengzachorywei mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT xiaopengsong mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT liujian mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT fengjiang mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT shuanglinwang mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT haiboli mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT yongbozhang mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT houzhentuo mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms AT thectrlyingroup mesenchymalstromalcellbiotherapyforparkinsonsdiseasepremotorsymptoms |